Jim Glazen

Dendreon: Media Spotlight Generates Hype and Hysteria

Don't flatter yourself dude. Your last Dendreon article had no responses until I spiced up the comments section. Still, it was only 5 responses and I was 2 of those.

I made a fortune on Dendreon by taking a monster long position in the $4 range before the FDA panel and hitting the exit button as soon as I saw Mitch Gold, Dendreon's CEO bailing out.

Dendreon Jumps on New Cancer Vaccine Report

Dendreon's trials failed to statistically slow tumor progression but also were not designed to measure survival as an endpoint. I fail to see how a change in FDA requirements for approving cancer vaccines would help Provenge gain approval sooner than thought.

Dendreon needs to complete the current trial which is not even fully enrolled yet.

Dendreon "investors" are about the dumbest of the dumb in my opinion. They ran the stock up to $11 per share on news that the FDA wanted Dendreon to complete the current trial only to watch the stock settle back down to $6.50.

In my opinion, Mitch Gold, CEO told you all you needed to know just days after the FDA panel. He dumped 200,000 shares at $13+. Anyone with half a brain should have followed him out the door and never look back.

I frankly believe that Provenge does add some benefit. It's definitely not a cure and might add 4 months of survival. $60,000 cancer treatments for 4 extra months of life is the reason our health care costs are skyrocketing. We need more research dollars devoted to prevention and healthy lifestyle habits.

Dendreon Jumps on New Cancer Vaccine Report

This is old news and it's incredible that the stock would surge on this. It just goes to show how much stupid money is still chasing after hopes and dreams.

lmao!